- ISIN
- CH0334081137
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 19, 2016
Highlights
- Market Cap
- $5.22B
- Enterprise Value
- $5.60B
- EPS (TTM)
- -$6.24
- Total Revenue (TTM)
- $4.10M
- Gross Profit (TTM)
- -$171.17M
- EBITDA (TTM)
- -$509.21M
- Year Range
- $44.12 - $78.48
- Target Price
- $63.00
- ROA (TTM)
- -20.86%
- ROE (TTM)
- -31.33%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CRSP Performance Chart
CRISPR Therapeutics AG (CRSP) is up 3.7% since the beginning of the year. At $54 per share, CRSP is trading 30.7% below its 52-week high of $78. Investors who bought $1,000 worth of CRSP shares 5 years ago would now be looking at an investment worth $416.
Loading charts...
Returns By Period
CRISPR Therapeutics AG (CRSP) has returned 3.66% so far this year and 22.85% over the past 12 months.
CRISPR Therapeutics AG
- 1D
- 0.50%
- 1M
- 7.94%
- YTD
- 3.66%
- 6M
- -6.13%
- 1Y
- 22.85%
- 3Y*
- -1.00%
- 5Y*
- -16.09%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
CRSP Monthly Returns History
Based on dividend-adjusted daily data since Oct 19, 2016, CRSP's average daily return is +0.13%, while the average monthly return is +2.82%. At this rate, an investment would double in approximately 2.1 years.
Historically, 52% of months were positive and 48% were negative. The best month was Nov 2023 with a return of +71.4%, while the worst month was Oct 2018 at -26.1%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.
On a daily basis, CRSP closed higher 49% of trading days. The best single day was Feb 25, 2019 with a return of +25.2%, while the worst single day was Dec 21, 2018 at -17.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.73% | 20.38% | -20.90% | 10.03% | 7.34% | -3.24% | 3.66% | ||||||
| 2025 | 5.67% | 5.60% | -22.52% | 13.64% | -6.15% | 34.03% | 15.67% | -7.87% | 25.04% | -1.27% | -16.44% | -1.93% | 33.23% |
| 2024 | 0.56% | 33.79% | -19.07% | -22.26% | 1.42% | 0.50% | 6.07% | -16.70% | -1.55% | -1.26% | 10.30% | -23.08% | -37.12% |
| 2023 | 25.51% | -3.33% | -8.29% | 8.20% | 30.85% | -12.34% | 2.12% | -12.77% | -9.24% | -14.23% | 71.41% | -6.19% | 54.00% |
| 2022 | -15.87% | -3.73% | 2.28% | -20.95% | 16.99% | 4.69% | 23.42% | -13.21% | 0.40% | -19.91% | 4.68% | -25.81% | -46.36% |
| 2021 | 8.22% | -24.15% | -3.06% | 7.73% | -9.97% | 36.99% | -25.25% | 3.25% | -10.42% | -18.40% | -12.52% | -5.16% | -50.51% |
Benchmark Metrics
CRISPR Therapeutics AG has an annualized alpha of 14.66%, beta of 1.37, and R2 of 0.15 versus S&P 500 Index. Calculated based on daily prices since October 19, 2016.
- This stock captured 179.09% of S&P 500 Index gains and 162.56% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.15 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 14.66%
- Beta
- 1.37
- R²
- 0.15
- Upside Capture
- 179.09%
- Downside Capture
- 162.56%
Return for Risk
Risk / Return Rank
CRSP ranks 54 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for CRISPR Therapeutics AG (CRSP) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CRSP | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.66 | ||
| Sortino ratioReturn per unit of downside risk | -1.76 | ||
| Omega ratioGain probability vs. loss probability | 1.11 | 1.37 | -0.25 |
| Calmar ratioReturn relative to maximum drawdown | 0.54 | 2.78 | -2.24 |
| Martin ratioReturn relative to average drawdown | 0.89 | 12.44 | -11.55 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the CRISPR Therapeutics AG. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the CRISPR Therapeutics AG was 85.11%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current CRISPR Therapeutics AG drawdown is 74.12%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -85.11%Apr 2025 | 4y 2mo | — | 5y 5moJan 2021 - now |
Rate-hike selloffLate 2018 | -69.11%Dec 2018 | 6mo 24d | 1y 6mo | 2y 24dMay 2018 - Jun 2020 |
2017 bear market2017 | -42.60%May 2017 | 3mo 1d | 7mo 6d | 10mo 7dMar 2017 - Jan 2018 |
2017 bear market2017 | -37.24%Feb 2017 | 1mo 5d | 19d | 1mo 24dJan 2017 - Feb 2017 |
2018 bear market2018 | -26.73%Apr 2018 | 19d | 1mo 14d | 2mo 3dMar 2018 - May 2018 |
Drawdown Indicators
| CRSP | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -85.11% | -56.78% | -28.33% |
Max Drawdown (1Y)Largest decline over 1 year | -42.25% | -9.10% | -33.15% |
Max Drawdown (3Y)Largest decline over 3 years | -64.91% | -18.90% | -46.01% |
Max Drawdown (5Y)Largest decline over 5 years | -80.68% | -25.43% | -55.25% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -74.12% | -1.80% | -72.32% |
Average DrawdownAverage peak-to-trough decline | -49.29% | -10.71% | -38.58% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 25.88% | 2.03% | +23.85% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of CRISPR Therapeutics AG over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how CRISPR Therapeutics AG is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CRSP relative to other companies in the Biotechnology industry. Currently, CRSP has a P/S ratio of 1,206.8. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CRSP in comparison with other companies in the Biotechnology industry. Currently, CRSP has a P/B value of 2.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CRSP
Add CRISPR Therapeutics AG to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CRSP